Abstract:Abstract Background Sodium–glucose linked transporter type 2 (SGLT-2) inhibition has been shown to reduce cardiovascular mortality in heart failure independently of glycemic control and prevents the onset of atrial arrhythmias, a common co-morbidity in heart failure with preserved ejection fraction (HFpEF). The mechanism behind these effects is not fully understood, and it remains unclear if they could be further enhanced by additional SGLT-1 inhibition. We investigated the effects of chronic treatment with the dual SGLT-1&2 inhibitor sotagliflozin on left atrial (LA) remodeling and cellular arrhythmogenesis (i.e. atrial cardiomyopathy) in a metabolic syndrome-related rat model of HFpEF. Methods 17 week-old ZSF-1 obese rats, a metabolic syndrome-related model of HFpEF, and wild type rats (Wistar Kyoto), were fed 30 mg/kg/d sotagliflozin for 6 weeks. At 23 weeks, LA were imaged in-vivo by echocardiography. In-vitro, Ca 2+ transients (CaT; electrically stimulated, caffeine-induced) and spontaneous Ca 2+ release were recorded by ratiometric microscopy using Ca 2+ -sensitive fluorescent dyes (Fura-2) during various experimental protocols. Mitochondrial structure (dye: Mitotracker), Ca 2+ buffer capacity (dye: Rhod-2), mitochondrial depolarization (dye: TMRE) and production of reactive oxygen species (dye: H2DCF) were visualized by confocal microscopy. Statistical analysis was performed with 2-way analysis of variance followed by post-hoc Bonferroni and student’s t-test, as applicable. Results Sotagliflozin ameliorated LA enlargement in HFpEF in-vivo. In-vitro , LA cardiomyocytes in HFpEF showed an increased incidence and amplitude of arrhythmic spontaneous Ca 2+ release events (SCaEs). Sotagliflozin significantly reduced the magnitude of SCaEs, while their frequency was unaffected. Sotagliflozin lowered diastolic [Ca 2+ ] of CaT at baseline and in response to glucose influx, possibly related to a ~ 50% increase of sodium sodium–calcium exchanger (NCX) forward-mode activity. Sotagliflozin prevented mitochondrial swelling and enhanced mitochondrial Ca 2+ buffer capacity in HFpEF. Sotagliflozin improved mitochondrial fission and reactive oxygen species (ROS) production during glucose starvation and averted Ca 2+ accumulation upon glycolytic inhibition. Conclusion The SGLT-1&2 inhibitor sotagliflozin ameliorated LA remodeling in metabolic HFpEF. It also improved distinct features of Ca 2+ -mediated cellular arrhythmogenesis in-vitro (i.e. magnitude of SCaEs, mitochondrial Ca 2+ buffer capacity, diastolic Ca 2+ accumulation, NCX activity). The safety and efficacy of combined SGLT-1&2 inhibition for the treatment and/or prevention of atrial cardiomyopathy associated arrhythmias should be further evaluated in clinical trials.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: **Whether the dual SGLT - 1 and SGLT - 2 inhibitor sotagliflozin can improve left atrial remodeling and cellular arrhythmia in heart failure with preserved ejection fraction (HFpEF) associated with metabolic syndrome**. Specifically, the researchers focused on: 1. **Left atrial (LA) remodeling**: The common left atrial enlargement in HFpEF patients and its impact on cardiac function. 2. **Cellular arrhythmia**: In particular, abnormal calcium ion cycling in atrial myocytes and mitochondrial dysfunction, which may lead to the occurrence of arrhythmias such as atrial fibrillation. 3. **Metabolic dysfunction**: Common metabolic disorders in HFpEF patients, such as impaired glucose metabolism and increased oxidative stress. To explore these issues, the researchers used the ZSF - 1 obese rat model, which is an HFpEF model associated with metabolic syndrome. Through long - term sotagliflozin treatment, the researchers evaluated its effects on left atrial remodeling, calcium ion cycling in atrial myocytes, mitochondrial function, and metabolic function. ### Main research contents: - **Left atrial remodeling**: Evaluate the changes in left atrial volume by echocardiography. - **Calcium ion cycling in atrial myocytes**: Record calcium transients (CaT) and spontaneous calcium release events (SCaEs) in atrial myocytes. - **Mitochondrial function**: Evaluate mitochondrial structure, calcium - buffering capacity, depolarization, and reactive oxygen species (ROS) generation. - **Metabolic function**: Detect the β - hydroxybutyric acid level in serum to evaluate the metabolic state. ### Research hypothesis: The researchers hypothesized that **chronic use of the dual SGLT - 1 and SGLT - 2 inhibitor sotagliflozin can reduce left atrial remodeling and improve calcium ion cycling and mitochondrial function in atrial myocytes, thereby reducing the occurrence of arrhythmias**. ### Research methods: - **Animal model**: Use the ZSF - 1 obese rat model, divided into a control group and a sotagliflozin - treated group. - **Echocardiography**: Evaluate the left atrial volume. - **Isolation of atrial myocytes**: Conduct measurements of calcium and mitochondrial functions. - **Fluorescence microscopy**: Record calcium transients and mitochondrial structure. - **Statistical analysis**: Use two - way analysis of variance (ANOVA) and post - hoc Bonferroni test for data processing. ### Expected results: - **Left atrial volume**: The left atrial volume in the sotagliflozin - treated group is significantly reduced. - **Calcium ion cycling**: The amplitude of spontaneous calcium release events in atrial myocytes in the sotagliflozin - treated group is decreased. - **Mitochondrial function**: Mitochondrial swelling in the sotagliflozin - treated group is reduced, and the calcium - buffering capacity is enhanced. - **Metabolic function**: The β - hydroxybutyric acid level in the serum of the sotagliflozin - treated group is increased, indicating an improvement in metabolic function. Through these studies, the authors hope to provide new ideas for the treatment of HFpEF patients, especially by combining SGLT - 1 and SGLT - 2 inhibitors to improve cardiac function and reduce the risk of arrhythmias.

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF